Show simple item record

dc.contributor.authorSaczynski, Jane S.
dc.contributor.authorSiggurdsson, Sigurdur
dc.contributor.authorJonsson, Palmi V.
dc.contributor.authorEiriksdottir, Gudny
dc.contributor.authorOlafsdottir, Elin
dc.contributor.authorKjartansson, Olafur
dc.contributor.authorHarris, Tamara B.
dc.contributor.authorvan Buchem, Mark A.
dc.contributor.authorGudnason, Vilmundur
dc.contributor.authorLauner, Lenore J.
dc.date2022-08-11T08:09:39.000
dc.date.accessioned2022-08-23T16:38:48Z
dc.date.available2022-08-23T16:38:48Z
dc.date.issued2009-06-11
dc.date.submitted2010-03-29
dc.identifier.citation<p>Diabetes Care. 2009 Sep;32(9):1608-13. Epub 2009 Jun 9. <a href="http://dx.doi.org/10.2337/dc08-2300">Link to article on publisher's site</a></p>
dc.identifier.issn0149-5992 (Linking)
dc.identifier.doi10.2337/dc08-2300
dc.identifier.pmid19509008
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39327
dc.description.abstractOBJECTIVE: To examine the association of glycemic status to magnetic resonance imaging indicators of brain pathological changes. RESEARCH DESIGN AND METHODS: This was a cross-sectional, population-based study of 4,415 men and women without dementia (mean age 76 years) participating in the Age Gene/Environment Susceptibility-Reykjavik Study. Glycemic status groups included the following: type 2 diabetes (self-report of diabetes, use of diabetes medications, or fasting blood glucose > or =7.0 mmol/l [11.1%]); impaired fasting glucose (IFG) (fasting blood glucose 5.6-6.9 mmol/l [36.2%]); and normoglycemic (52.7%). Outcomes were total brain volume, white and gray matter volume, white matter lesion (WML) volume, and presence of cerebral infarcts. RESULTS: After adjustment for demographic and cardiovascular risk factors, participants with type 2 diabetes had significantly lower total brain volume (72.2 vs. 71.5%; P < 0.001) and lower gray and white matter volumes (45.1 vs. 44.9%, P < 0.01 and 25.7 vs. 25.3%, P < 0.001, respectively) and were more likely to have single (odds ratio 1.45 [95% CI 1.14-1.85]) or multiple (2.27 [1.60-3.23]) cerebral infarcts compared with normoglycemic participants. Longer duration of type 2 diabetes was associated with lower total brain volume and gray and white matter volume, higher WML volume (all P(trend) < 0.05), and a greater likelihood of single and multiple cerebral infarcts (all P(trend) < 0.01). CONCLUSIONS: Type 2 diabetic participants have more pronounced brain atrophy and are more likely to have cerebral infarcts. Duration of type 2 diabetes is associated with brain changes, suggesting that type 2 diabetes has a cumulative effect on the brain.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19509008&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subjectAge Factors
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectBrain Injuries
dc.subjectCerebral Infarction
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDisease Susceptibility
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectSex Factors
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleGlycemic status and brain injury in older individuals: the age gene/environment susceptibility-Reykjavik study
dc.typeJournal Article
dc.source.journaltitleDiabetes care
dc.source.volume32
dc.source.issue9
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=3126&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/2127
dc.identifier.contextkey1250260
refterms.dateFOA2022-08-23T16:38:48Z
html.description.abstract<p>OBJECTIVE: To examine the association of glycemic status to magnetic resonance imaging indicators of brain pathological changes.</p> <p>RESEARCH DESIGN AND METHODS: This was a cross-sectional, population-based study of 4,415 men and women without dementia (mean age 76 years) participating in the Age Gene/Environment Susceptibility-Reykjavik Study. Glycemic status groups included the following: type 2 diabetes (self-report of diabetes, use of diabetes medications, or fasting blood glucose > or =7.0 mmol/l [11.1%]); impaired fasting glucose (IFG) (fasting blood glucose 5.6-6.9 mmol/l [36.2%]); and normoglycemic (52.7%). Outcomes were total brain volume, white and gray matter volume, white matter lesion (WML) volume, and presence of cerebral infarcts.</p> <p>RESULTS: After adjustment for demographic and cardiovascular risk factors, participants with type 2 diabetes had significantly lower total brain volume (72.2 vs. 71.5%; P < 0.001) and lower gray and white matter volumes (45.1 vs. 44.9%, P < 0.01 and 25.7 vs. 25.3%, P < 0.001, respectively) and were more likely to have single (odds ratio 1.45 [95% CI 1.14-1.85]) or multiple (2.27 [1.60-3.23]) cerebral infarcts compared with normoglycemic participants. Longer duration of type 2 diabetes was associated with lower total brain volume and gray and white matter volume, higher WML volume (all P(trend) < 0.05), and a greater likelihood of single and multiple cerebral infarcts (all P(trend) < 0.01).</p> <p>CONCLUSIONS: Type 2 diabetic participants have more pronounced brain atrophy and are more likely to have cerebral infarcts. Duration of type 2 diabetes is associated with brain changes, suggesting that type 2 diabetes has a cumulative effect on the brain.</p>
dc.identifier.submissionpathoapubs/2127
dc.contributor.departmentDepartment of Medicine, Division of Geriatric Medicine
dc.source.pages1608-13


Files in this item

Thumbnail
Name:
1608.full.pdf
Size:
83.09Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Except where otherwise noted, this item's license is described as © 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.